* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
|Catalog||Product Name||CAS Number||Inquiry|
|BP-400001||PROTAC AR Degrader-4||1351169-31-7||Inquiry|
|BP-400002||PROTAC MDM2 Degrader-3||2249750-23-8||Inquiry|
|BP-400048||PROTAC BRD9 Degrader-1||2097971-01-0||Inquiry|
|BP-400049||PROTAC Sirt2 Degrader-1||2098487-75-1||Inquiry|
|BP-400051||PROTAC CDK9 Degrader-1||2118356-96-8||Inquiry|
|BP-400053||PROTAC ER Degrader-3||2158322-29-1||Inquiry|
|BP-400058||Gefitinib-based PROTAC 3||2230821-27-7||Inquiry|
|BP-400059||PROTAC FLT-3 degrader 1||2230826-81-8||Inquiry|
|BP-400062||PROTAC MDM2 Degrader-4||2249750-24-9||Inquiry|
|BP-400063||PROTAC MDM2 Degrader-1||2249944-98-5||Inquiry|
|BP-400064||PROTAC MDM2 Degrader-2||2249944-99-6||Inquiry|
Protac® is the abbreviation for proteolysis targeting chimera, which is a small bifunctional molecule. One end of the molecule is a ligand that binds the target protein and the other end is a ligand that binds E3 ubiquitin ligase. The two ends are connected by a chain. In vivo, the target protein and E3 ubiquitin ligase can be drawn closer, so that the target protein is labeled with ubiquitin and then degraded by the ubiquitin-proteasome pathway. This is a brand-new drug design strategy. By designing such triplet small molecule drugs, theoretically, any over-expressed and mutated pathogenic protein can be eliminated for the purpose of treating the disease.
From the first generation peptide fragment- based Protacs to the second generation of small molecule Protac® designs that began in 2008, degraded target proteins range from the earliest methionyl aminopeptidase 2, androgen receptor, cellular retinoic acid binding protein, etc., to the most recent estrogen receptor, Tau microtubule-related proteins, kinases, etc. They have been used to treat diseases including cancer, rheumatoid, and neurodegenerative diseases. After the upsurge of small-molecule Protacs in 2015, Dr. Deshaies made the point that Protacs had the potential to be a major new drug and could surpass protein kinase inhibitors and monoclonal antibodies, two of the hottest areas of drug development. So far, BRD4, RIPK2, ERRα, BRD9, TBK1, Sirt2, CDK9, p38α, Pirin, c-Met, EGFR, FAK, FLT3 and other proteins have been reported to be degraded using Protac® technology.
Currently, Protac® is mainly used to discover new anticancer agents because they have unique advantages over classic inhibitors. Arvinas planned to launch a clinical trial of the Protac® strategy for prostate cancer in 2019, which would last approximately 9 months. Arvinas has released the latest data on its Protac® therapy: in two phase 1 clinical trials, its leading therapies ARV-110 and ARV-471 have achieved well-tolerated results. ARV-110 is a bifunctional molecule, one end of which can bind to a target-androgen receptor (AR) for this treatment in progress. The other end can bind to E3 ubiquitin ligase. Ligase can "tag" the target with ubiquitin, allowing the target protein to be degraded by the proteasomes that are transported to the cell. ARV-471 can degrade estrogen receptors and treat breast cancer. Not only that, Arvinas has also claimed an in vivo evidence that Protac® can reduce the tau protein in the mouse brain. Injecting its tau protein degradation agent directly into the mouse hippocampus reduced the tau level by 50%. From this perspective, the Protac® strategy (protein degradation instead of inhibition) can be used as a general and powerful treatment method for Alzheimer's disease and cancer in the future.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.